scholarly journals Differential Diagnosis between Oral Metastasis of Renal Cell Carcinoma and Salivary Gland Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 506
Author(s):  
Yoshihiro Morita ◽  
Kana Kashima ◽  
Mao Suzuki ◽  
Hiroko Kinosada ◽  
Akari Teramoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Differential Diagnosis ◽  
Salivary Gland ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Malignant Tumors ◽  
Metastatic Cancer ◽  
Salivary Gland Cancer ◽  
Clear Cells

Renal cell carcinoma, which has clear cells in 70% of cases, has a high frequency of hematogenous distant metastases to lung, bone, liver, and other areas. Metastatic cancer accounts for 1 to 3% of malignant tumors in the stomatognathic region, and the metastasis of renal cell carcinoma to the oral mucosal tissue, though extremely rare, does occur. In addition, clear cells have been observed in some salivary gland cancers in the oral cavity. Therefore, the differential diagnosis of metastatic renal cell carcinoma and salivary gland cancer is important. This review discusses the differential diagnosis between metastatic renal cell carcinoma and malignant tumors of the salivary gland.

Immunophenotypic Comparison of Salivary Gland Oncocytoma and Metastatic Renal Cell Carcinoma

2005 ◽  
Vol 115 (6) ◽  
pp. 1097-1100 ◽  
Author(s):  
John A. Ozolek ◽  
Sheldon I. Bastacky ◽  
Eugene N. Myers ◽  
Jennifer L. Hunt
Keyword(s):  
Renal Cell Carcinoma ◽  
Salivary Gland ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 116-116
Author(s):  
Lisa Spees ◽  
Michaela Ann Dinan ◽  
Bradford E. Jackson ◽  
Christopher Baggett ◽  
Lauren E. Wilson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Clinical Characteristics ◽  
De Novo ◽  
Metastatic Cancer ◽  
All Cause Mortality ◽  
Insured Patients ◽  
Privately Insured

116 Background: It is important to understand how emerging new therapies, such as oral anti-cancer agents (OAAs), diffuse across and can improve outcomes within real-world populations, which include age groups and racial groups not well-represented in clinical trials, such as people older than age 65 and Black patients. Our objectives were to examine whether disparities in mortality persist among patients with metastatic renal cell carcinoma (mRCC) receiving OAAs and whether these disparities may be partially explained by patient’s clinical characteristics or provider-level factors. Methods: We used linked state cancer registry data and multi-payer claims data to identify patients with mRCC who were diagnosed in 2004 through 2015 and had initiated an OAA and survived ≥ 90 days after initiating. Provider data were obtained from North Carolina Health Professions Data System and the National Plan & Provider Enumeration System. A patient’s modal provider was the provider most frequently on claims with a diagnosis code of RCC or metastatic cancer between 2 months prior to and 3 months following the index date. We estimated hazard ratios (HR) and corresponding 95% confidence limits (CL) using Cox proportional hazard models to evaluate which patient demographics, patient clinical characteristics, and provider-level factors were associated with 2-year all-cause mortality. Results: The cohort included 207 patients with mRCC. In unadjusted analyses, public insurance (Medicaid or Medicare), de novo metastatic diagnosis, frailty, polypharmacy, and a visit to a skilled nursing facility were associated with increased all-cause mortality. In multivariable models, clinical variables such as frailty (HR: 1.36, 95% CL: 1.11-1.67) and de novo metastatic diagnosis (HR: 2.63, 95%CL: 1.67-4.16) were associated with higher all-cause mortality. Additionally, Medicare-insured patients continued to have higher all-cause mortality compared to privately insured patients (HR: 2.35, 95% CL: 1.32-4.18). None of the provider-level covariates (i.e., specialization, experience, volume, or practice location) investigated were associated with all-cause mortality. Conclusions: Even when adjusting for age, frailty, and comorbidities, Medicare-insured patient had lower overall survival than privately-insured patients. Patient survival did not differ based on modal provider’s characteristics.

scholarly journals Metastatic Renal Cell Carcinoma Presenting as a Paranasal Sinus Mass: The Importance of Differential Diagnosis

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Massimo Ralli ◽  
Giancarlo Altissimi ◽  
Rosaria Turchetta ◽  
Mario Rigante
Keyword(s):  
Renal Cell Carcinoma ◽  
Differential Diagnosis ◽  
Ct Scan ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Early Stage ◽  
Left Kidney ◽  
Intracranial Extension ◽  
The Right

Metastases in the paranasal sinuses are rare; renal cell carcinoma is the most common cancer that metastasizes to this region. We present the case of a patient with a 4-month history of a rapidly growing mass of the nasal pyramid following a nasal trauma, associated with spontaneous epistaxis and multiple episodes of hematuria. Cranial CT scan and MRI showed an ethmoid mass extending to the choanal region, the right orbit, and the right frontal sinus with an initial intracranial extension. Patient underwent surgery with a trans-sinusal frontal approach using a bicoronal incision combined with an anterior midfacial degloving; histological exam was compatible with a metastasis of clear cell renal cell carcinoma. Following histological findings, a total body CT scan showed a solitary 6 cm mass in the upper posterior pole of the left kidney identified as the primary tumor. Although rare, metastatic renal cell carcinoma should always be suspected in patients with nasal or paranasal masses, especially if associated with symptoms suggestive of a systemic involvement such as hematuria. A correct early-stage diagnosis of metastatic RCC can considerably improve survival rate in these patients; preoperative differential diagnosis with contrast-enhanced imaging is fundamental for the correct treatment and follow-up strategy.

Metastatic Renal Cell Carcinoma Presenting as Foot Metastasis

2011 ◽  
Vol 101 (3) ◽  
pp. 265-268 ◽  
Author(s):  
Elie Choufani ◽  
Jerome Diligent ◽  
Laurent Galois ◽  
Didier Mainard
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Malignant Tumors ◽  
Rare Condition ◽  
Delay In Diagnosis ◽  
Disseminated Disease ◽  
Late Manifestation

Malignant tumors frequently metastasize to bone centrally in the skeleton. Metastatic disease distal to the knee is unusual. Metastasis to the foot (acrometastasis) is rare (0.01%) and is usually a late manifestation of disseminated disease. The purpose of this article is to present a rare case of metastatic renal cell carcinoma with foot metastasis as the primary manifestation along with another rare localization of metastatic disease distal to the knee, in the contralateral tibial diaphysis. To highlight the delay in diagnosis of such a rare condition to consider it in the diagnosis of a painful foot, we also present a review of the literature. (J Am Podiatr Med Assoc 101(3): 265–268, 2011)

scholarly journals p63 Immunohistochemistry Differentiates Salivary Gland Oncocytoma and Oncocytic Carcinoma from Metastatic Renal Cell Carcinoma

2007 ◽  
Vol 1 (2) ◽  
pp. 123-131 ◽  
Author(s):  
Jonathan B. McHugh ◽  
Aaron P. Hoschar ◽  
Mari Dvorakova ◽  
Anil V. Parwani ◽  
E. Leon Barnes ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Salivary Gland ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Oncocytic Carcinoma

scholarly journals Metastatic Renal Cell Carcinoma: The Importance of Immunohistochemistry in Differential Diagnosis

2012 ◽  
Vol 5 (1) ◽  
pp. 30-34 ◽  
Author(s):  
Sandra Custódio ◽  
Ana Joaquim ◽  
Vânia Peixoto ◽  
Joana Espiga Macedo ◽  
Ana Luísa Faria ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Differential Diagnosis ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

scholarly journals Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 87-87
Author(s):  
Lisa Spees ◽  
Stephanie B. Wheeler ◽  
Bradford E. Jackson ◽  
Christopher Baggett ◽  
Lauren E. Wilson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Index Date ◽  
Metastatic Cancer ◽  
Private Insurance ◽  
Initial Diagnosis ◽  
Patient Level ◽  
Race Ethnicity

87 Background: While several patient-level factors have been associated with oral anti-cancer agent (OAA) initiation and adherence for metastatic renal cell carcinoma (mRCC) and other cancers, few provider-level factors have been examined, despite providers being a key component driving OAA access. We examined provider and patient characteristics associated with OAA initiation and adherence among individuals with mRCC. Methods: We used linked North Carolina state cancer registry data and multi-payer claims data to identify mRCC patients diagnosed in 2004-2015. A patient’s modal provider was the provider most frequently on claims with a diagnosis code of RCC or metastatic cancer between 2 months prior to and 3 months following the index date. Provider-level variables included specialty, sex, race/ethnicity, years in practice, provider’s RCC patient volume, and practice location. Patient-level control variables of interest included: age at metastatic diagnosis, sex, race/ethnicity, rural location, insurance coverage at metastatic index date, histology, stage at initial diagnosis, radical/partial nephrectomy in the prior year, number of comorbidities at baseline, and frailty. OAA initiation within the 12 months following the patient’s metastatic index date was identified from prescription drug files and pharmacy claims. Adherence to OAAs was defined as having ≥80% proportion of days covered (PDC) for the 90 consecutive days following an initial OAA claim that patients had access to any OAA days’ supply. We estimated risk ratios (RR) and corresponding 95% confidence limits (CL) using modified Poisson regression to evaluate patient- and provider-level factors associated with OAA initiation and adherence. Results: Of the 687 patients in our sample, 37% initiated an OAA following mRCC diagnosis. Patients with a modal provider specializing in hematology/medical oncology were more likely to initiate OAAs than those seen by other specialties (i.e., urology/urological surgery, internal medicine, and other). Compared to patients treated by providers practicing in both urban and rural areas, patients with providers practicing in urban areas only more likely to initiate OAAs (RR = 1.37; 95%CL:1.09,1.73). Patients who were older, with more comorbid conditions, stage I at initial diagnosis, and greater frailty were less likely to initiate OAAs. Among the 207 patients who initiated an OAA and survived the following 90 days, the median PDC was 0.91. No provider-level factors were associated with OAA adherence. However, Medicare-insured patients were less likely to be adherent (RR = 0.61; 95%CL:0.42,0.87) than those with private insurance. Conclusions: Our results suggest that provider- and patient-level factors are associated with OAA initiation but only patient-level factors are associated with adherence.

Nodular Vascular Transformation of the Lymph Node Sinuses Mimicking Sarcomatoid Change in Renal Cell Carcinoma: A Potential Diagnostic Pitfall

2020 ◽  
Vol 28 (6) ◽  
pp. 637-642
Author(s):  
Salvatore E. Mignano ◽  
Daniel H. Russell
Keyword(s):  
Renal Cell Carcinoma ◽  
Lymph Node ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Metastatic Cancer ◽  
Tumor Grading ◽  
Cell Renal Cell Carcinoma ◽  
Diagnostic Pitfall ◽  
Sarcomatoid Differentiation

Vascular transformation of the lymph node sinuses (VTS) is an uncommon phenomenon that is believed to occur secondary to obstruction of efferent lymphatics, frequently occuring in retroperitoneal lymph nodes draining cancer. The nodular subtype of VTS, in particular, can mimic metastatic cancer, such as metastatic renal cell carcinoma with sarcomatoid differentiation, potentially resulting in inaccurate tumor grading and/or staging. We present a case of nodular VTS mimicking metastatic renal cell carcinoma with sarcomatoid differentiation in a patient with high-grade clear cell renal cell carcinoma, and explore the relevant differential diagnosis. Awareness of VTS is essential to avoid misdiagnosis of this benign and curative condition.

Sign in / Sign up

Export Citation Format

Share Document